HIGHLIGHTS
- who: Mohammed Fasihul Alam from the (UNIVERSITY) have published the research work: Infliximab versus ciclosporin in steroid resistant acute severe ulcerative colitis: a model-based cost-utility analysis of data from CONSTRUCT pragmatic trial, in the Journal: (JOURNAL)
- what: The study aimed to perform decision analytic model-based longterm cost-utility analysis (CUA) of infliximab versus ciclosporin for steroid-resistant ASUC investigated in CONSTRUCT pragmatic trial. Details on NHS resource uses, how these were captured and their costs (in 2012-13 prices in Great Britain Pound (GBP) sterling) were reported in the CONSTRUCT main report . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.